Archive | Longevity Health RSS feed for this section

Announcing Healthtech Partnering Week, March 15-19, 2021

21 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) is pleased to announce the next Healthtech Partnering Week takes place March 15-19, 2021. Super early bird registrations save $100 when they sign up by January 29!

Healthtech Partnering Week is an early-stage fundraising vessel, featuring three back-to-back digital partnering conferences: Redefining Early Stage Investments (RESI), 4D Meets AI, and Longevity, Health & Innovation (LHI), which is co-organized with Mary Furlong & Associates. The previous Healthtech Partnering Week, held in conjuncture with J.P. Morgan’s virtual Health Care Conference, hosted 20 panels, 10 live pitch sessions, 2,000+ meetings, and welcomed 600+ investors actively seeking opportunities in healthcare and life science.

Each conference is designed for early-stage fundraising executives to reach potential partners based on product fit and stage of development. Many have begun relationships that have led to millions invested. LSN is proud to be a regular part of the early-stage fundraising ecosystem within life science and healthcare and invites you to join us in March!

Learn More at www.healthtechpartneringweek.com.

xCures is the Longevity, Health & Innovation Pitch Challenge Winner!

21 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

Longevity, Health & Innovation (LHI), co-organized by Life Science Nation (LSN) and Mary Furlong & Associates, hosted the Innovator’s Pitch Challenge (IPC) last week, January 14-15, 2021. Ten pitching companies representing early-stage innovation within digital health, medical devices, and therapeutics took part in two live sessions, during which they pitched live to a panel of investor judges. Attendees and judges voted on the best pitch, and we’re pleased to announce that xCures is the winner of LHI’s Innovator’s Pitch Challenge! Check out the xCures dedicated pitch page and get to know CEO Mika Newton and the xCures team in our recent interview.

Rory McCann(RM): Hi Mika, Congratulations on being selected as the Innovator’s Pitch Challenge winner at Longevity, Health & Innovation. Tell us a little about yourself and xCures.

Mika Newton(MN): I got involved with xCures after losing several close family members to cancer. I had spent 20+ years in the life sciences, primarily developing and commercializing computational technology from early discovery through market access and commercial applications. My projects involved biopharmaceutical, diagnostics, medical societies, and governments, but the impact of what I was working on was always at an aggregate level. With xCures, the impact is direct to the patient.

xCures empowers advanced cancer patients by identifying the best treatment options for them to consider with their physician, tracking their outcomes and continuously learning from every interaction. By maximizing the value of the interaction between patients and their physicians, the platform captures valuable insights and knowledge in real-time to help others. xCures’ partners use this real-world evidence (RWE) to advance the development and commercialization of their products and services.

RM: What is the need in the marketplace you’re filling and how have you found a solution to that need?

MN: There are more than 600,000 advanced cancer patients in the US, of which less than 50,000 can get into clinical trials. xCures makes it possible to learn from the experiences of all patients who give us their data in return for treatment options. xCures’ AI algorithms use these data to continuously learn from every patient and optimize options for future use. Using these tools, xCures provides doctors, hospitals, and payors with life-saving decision support services.

Patients participate with their data. They sign a HIPAA release giving xCures the right to request their medical records. The records are routinely collected from the treating facility as PDFs or fax. These documents are automatically structured into a crisp case summary for use by the patients and their doctors.

Our partners developing and commercializing products and services for the advanced cancer patient use the platform to generate valuable RWE, which is used to accelerate the development of new medicines, expand the approved uses of existing therapies, and demonstrate value for reimbursement.

RM: How did you go about building your team? What considerations did you take into account when developing the people behind xCures?

MN: To build the xCures platform, we assembled a world-class team experienced in artificial intelligence, data science, technology, biology, clinical development and medical product commercialization. Our advisors include leading oncologists and cancer researchers, a MacArthur Fellow, and business leaders with decades of startup experience. The personal nature of the value that our technology creates is a deep motivating factor for all of us. Our culture is built on the premise of accountability to the team and achieving the best outcomes for patients and the project. All of our team members have been motivated by the opportunity to do well by doing good. The more good we do, the better our business does.

RM: What have been some of the biggest hurdles you’ve faced with early-stage fundraising? How have you tackled some of these challenges?

MN: The xCures concept was created with enthusiasm across the investor space. The biggest hurdles have been proving that the vision is attainable from an operational and business perspective. Over the last two years, we have solved three key technical challenges. First, we solved for how to get a deep clinical understanding of cancer patients and generate longitudinal data without adding any additional administrative burden to the system. Second, we applied our tools to create a living master catalog of all the potential cancer treatments, including the options, medical rationales for their use, and access pathways. Lastly, we developed a suite of tools to match patients to a short list of appropriate options, rank the options using predictive models, and convene virtual tumor boards to mine expert insights.

With this working, we were able to launch a number of partner programs on the platform to validate our business model. For example, the first pharmaceutical company to make a product available on the platform accelerated its brain cancer drug development by more than 18 months and received Rare Pediatric Disease, Fast Track, and Orphan Drug designations. Another company uses xCures to make its targeted therapy available to pancreatic, ovarian, colon, melanoma, breast, and lung cancer patients. It will use data from these patients to prioritize future trials.

RM: What’s next for xCures? Where do you see the company in 1 year? 5 years? 10?

MN: Our goal for 2021 is to help 2,000 advanced cancer patients, and we are planning to scale to 10,000 by 2022. This scale – in conjunction with the fact that xCures learns from all patients, all physicians, all therapies, all the time – creates the network needed to power a learning health system. xCures’ platform and data will connect additional stakeholders across the oncology ecosystem through SaaS-based services to payers, providers, and labs that help patients beat cancer.

Registration is now open for Longevity, Health & Innovation, March 18-19, 2021! Save $100 on registration by January 29. The LHI Innovator’s Pitch Challenge is also accepting applications for March, learn more and apply at https://longevityhealthinnovation.com/pitch-challenge/.

Innovator’s Pitch Challenge Applications Open at LSN Healthtech Partnering Week

21 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireLife Science Nation (LSN)’s Healthtech Partnering Week serves as a vehicle for early-stage fundraising within life science and healthcare with many valuable features, including a match-based partnering system and hours of educational materials like entrepreneur bootcamps, branding workshops, and investor panels. However, one of the most powerful additions to the digital partnering space is the Innovator’s Pitch Challenge (IPC).

The IPC highlights exceptional early-stage companies and provides them the opportunity to pitch live to a panel of investor judges. Accepted companies submit pitching materials, including a pitch deck, executive summary, and a long-form pitch video that are sent to judges to review prior to live Q&A sessions. During the live session, each company will present a brief elevator pitch and participate in a Q&A from the judges and audience.

IPC applications are open until Friday, February 19th. Accepted applicants who sign up before Friday, January 29 will also save $100 on registration. Learn more about the IPC and how it can help boost your exposure and increase visibility to hundreds of investors and strategic partners!

Longevity, Health & Innovation’s Innovator’s Pitch Challenge Finalists

14 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

Hosting live pitch sessions has long been an important element in Life Science Nation (LSN)’s partnering conferences. These sessions help companies get their message out to investors who are a fit for their technology and stage of development. On behalf of conference organizers, LSN and Mary Furlong & Associates, we are pleased to highlight the following ten companies participating in the Innovator’s Pitch Challenge this week:

Longevity, Health & Innovation’s Innovator’s Pitch Challenge Finalists

Please click the logo to learn more about these companies, their teams, products, and technology. To learn more about the conference and Innovator’s Pitch Challenge, visit https://longevityhealthinnovation.com/pitch-challenge/.

The Lost Art of Following Up

14 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Following up with a previous correspondence is an inevitability in the digital age, so when did entrepreneurs start taking a lack of response as the recipient’s lack of interest in their message? While this may be true in some instances, it is not always the case. A timely, thoughtful follow-up strategy is one of the best communication tools any fundraising executive may possess, and it often makes the difference between a meeting and another introduction gone unanswered. Such a powerful skillset deserves its own process, so we’ve broken it down:

  1. Introduction: The first message is the one where you introduce yourself and your company, as well as request a meeting. It’s ok if your target investor does not respond immediately (hence this system). To help them understand your position, it’s important to include the following:
      1. Company tagline (5-6 words explaining who you are and what you do)
      2. Elevator pitch (1-3 sentences describing the company and tech)
      3. Technology differentiation, product innovation, or market position
      4. Raise and milestone information
  2. Follow Up 1 (Product/Tech): Why is your product and technology unique? Is it first-in-class? Best-in-class? This is your opportunity to dive into your company’s differentiated value.
  3. Follow Up 2 (Management/Team): Highlight your management and team. How have your people had a notable impact on the business development. What makes your people special?
  4. Follow Up 3 (One Pager): Condense all the important messages you’ve already shared into a one-page tear sheet for quick and easy reference later. Even if the investor you’ve targeted is not a fit, this will make it easier for them to share your company with another.

(Tear Sheet Sample)

Life Science Nation (LSN) has helped hundreds of early-stage startups within life science and healthcare get their branding and messaging straight in order to connect with investors who are a fit for their product and stage of development. We’ve seen great companies neglect the finer details, like a comprehensive follow-up strategy, and hope this helps you along your journey to funding and beyond!

Introducing the Innovator’s Pitch Challenge Finalists!

7 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireLife Science Nation (LSN)’s Inaugural Healthtech Partnering Week launches next week, which means the Innovator’s Pitch Challenge (IPC) is on! The IPC is an opportunity for early-stage, fundraising CEOs to pitch directly to a panel of judges, who follow up with a live Q&A session.

How does it work? The finalist companies deliver pitching materials, including a comprehensive slide deck, executive summary, and a long form pitch video to be hosted on a dedicated webpage the judges review prior to their live session. Sessions are split up by sectors and are designed to match up companies with investors actively seeking opportunities in their space. During the live session, companies deliver a brief short form pitch, which is then followed by a Q&A period with the judges.

Each event sees an incredible line up of early-stage companies delivering promising tech to advance life science and healthcare. LSN is proud to host this powerful meeting of the minds.

Innovator’s Pitch Challenge Finalists

J.P. Morgan Week Update: The Perfect Venue to Launch LSN Healthtech Partnering Week

7 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

It’s that time of year again! J.P. Morgan’s Annual Healthcare Conference has spawned countless concurrent healthcare conferences taking advantage of the influx of industry professionals eager to network and make deals for nearly forty years. The Redefining Early-Stage Investments (RESI) conference series has been a popular addition for several years, and it seemed the obvious choice when we looked to launch our own Healthtech Partnering Week.

Over the past ten months, as many industries slowed down, Life Science Nation (LSN)’s partnering events have ramped up, delivering an increased number of one-on-one meetings between fundraising early-stage companies and investors. The metrics speak for themselves, as we’ve seen an average of 1400+ meetings take place over three days of digital partnering, proving that digital partnering works with investors pulling the deal-making trigger. The proof-of-concept, preclinical and clinical trial money is flowing.

Learn more about Healthtech Partnering Week and join the 500+ investors.

What’s the difference?

MATCHING LSN’s customized partnering system enables fundraising CEOs, investors, and strategic partners to seek opportunities based on several search criteria, most importantly including product fit and stage of development, helping attendees avoid wasted meetings, which can amount to more than half the meetings booked at standard partnering conferences. LSN’s database of thousands of investors and start-ups provides detailed profiles that help attendees increase their chances of success by matching with the best partners for them.

MESSAGING LSN has interviewed thousands of investors in order to learn what their criteria are for taking a meeting and engaging with an investment prospect. The trends we found have been written into a book (FREE PDF COPY) designed to help the scientist-entrepreneur understand how to get their branding and messaging straight. This starts with a cogent 5–7-word tagline, a lucid 6-7-sentence elevator pitch, and a one-page data sheet that succinctly presents all relevant information a potential investor would need at first glance. Finally, tell your unique story through a two-page executive summary and elaborate on your technology in a 10–12-page pitch deck.

FOLLOW-UP Partnering is an extremely competitive contact sport. You need to get your company and message above the noise. Investors and strategic partners are inundated with meeting requests, and if you do not have a compelling tactical plan to go after and secure meetings, you run the risk of getting only 4-6 meetings, instead of 15-20+. It’s a numbers game – we don’t make the rules, but we know how to play by them.

LSN has developed a 4-step follow-up process. The concept of follow-up stops most early-stage entrepreneurs in their tracks and thus limits their interaction with targeted partners. We walk a fundraising CEO through all these issues and set them on the right path through our content, bootcamps and seminars. Preparing CEOs for partnering success is rarely given enough attention, and LSN is passionate about using its insight to help deal-flow to promising teams and their tech.

Check out more tips on partnering and a tutorial of the LSN system. There’s still time to register for events at Healthtech Partnering Week. Don’t miss out!

%d bloggers like this: